Document is current

Article History

Received: 13 March 2019

Accepted: 15 November 2019

First Online: 10 December 2019

Competing interests

: K.L. has, during the past 5 years, received honoraria for educational activities and lectures from AstraZeneca, GlaxoSmithKline, TEVA, and Novartis and has served on advisory boards arranged by Novartis and Boehringer Ingelheim. She has also participated in the steering committee for this study funded by Novartis. K. Larsson has, during the past 5 years, on one or more occasion served in an advisory board, served as a speaker, and/or participated in education activities arranged by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Takeda, Novartis, Chiesi, Orion, and Teva. C.J. has received honoraria for educational activities and lectures from Novartis, AstraZeneca, GlaxoSmithKline, TEVA, and Boehringer Ingelheim outside the submitted work. B.S. has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, MEDA, and TEVA and has served on advisory boards arranged by AstraZeneca, Novartis, GSK, Boehringer Ingelheim, and MEDA. I.T. has received honoraria for lectures and participation in advisory boards from Novartis, GlaxoSmithKline, Boehringer Ingelheim, and Menarini. The authors report no other competing interest related to this manuscript. F.S.G. and K.M. are employees of Novartis Pharma AG. B.K.B. and L.J. are employees of IQVIA, who received remuneration in relation to statistical analyses. G.J. has participated in the steering committee organized by Novartis for this study and served on advisory boards arranged by AstraZeneca, Novo Nordisk, and Takeda.